

The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies

DENNIS G. MAKI, MD; DANIEL M. KLUGER, MD; AND CHRISTOPHER J. CRNICH, MD

OBJECTIVE: To better understand the absolute and relative risks of bloodstream infection (BSI) associated with the various types of intravascular devices (IVDs), we analyzed 200 published studies of adults in which every device in the study population was prospectively evaluated for evidence of associated infection and microbiologically based criteria were used to define IVD-related BSI.

METHODS: English-language reports of prospective studies of adults published between January 1, 1966, and July 1, 2005, were identified by MEDLINE search using the following general search strategy: bacteremia [Medical Subject Heading, MeSH] OR septicemia [MeSH] OR bloodstream infection AND the specific type of intravascular device (eg, central venous port). Mean rates of IVD-related BSI were calculated from pooled data for each type of device and expressed as BSIs per 100 IVDs (%) and per 1000 IVD days.

RESULTS: Point incidence rates of IVD-related BSI were lowest with peripheral intravenous catheters (0.1%, 0.5 per 1000 IVD-days) and midline catheters (0.4%, 0.2 per 1000 catheter-days). Far higher rates were seen with short-term noncuffed and nonmedicated central venous catheters (CVCs) (4.4%, 2.7 per 1000 catheter-days). Arterial catheters used for hemodynamic monitoring (0.8%, 1.7 per 1000 catheter-days) and peripherally inserted central catheters used in hospitalized patients (2.4%, 2.1 per 1000 catheter-days) posed risks approaching those seen with short-term conventional CVCs used in the intensive care unit. Surgically implanted long-term central venous devices—cuffed and tunneled catheters (22.5%, 1.6 per 1000 IVD-days) and central venous ports (3.6%, 0.1 per 1000 IVD-days)—appear to have high rates of infection when risk is expressed as BSIs per 100 IVDs but actually pose much lower risk when rates are expressed per 1000 IVD-days. The use of cuffed and tunneled dual lumen CVCs rather than noncuffed, nontunneled catheters for temporary hemodialysis and novel preventive technologies, such as CVCs with anti-infective surfaces, was associated with considerably lower rates of catheter-related BSI.

CONCLUSIONS: Expressing risk of IVD-related BSI per 1000 IVD-days rather than BSIs per 100 IVDs allows for more meaningful estimates of risk. These data, based on prospective studies in which every IVD in the study cohort was analyzed for evidence of infection by microbiologically based criteria, show that *all* types of IVDs pose a risk of IVD-related BSI and can be used for benchmarking rates of infection caused by the various types of IVDs in use at the present time. Since almost all the national effort and progress to date to reduce the risk of IVD-related infection have focused on short-term noncuffed CVCs used in intensive care units, infection control programs must now strive to consistently apply essential control measures and preventive technologies with *all* types of IVDs.

Mayo Clin Proc. 2006;81(9):1159-1171

BSI = bloodstream infection; CDC = Centers for Disease Control and Prevention; CVC = central venous catheter; ICU = intensive care unit; IV = intravenous; IVD = intravascular device; PA = pulmonary artery; PICC = peripherally inserted central venous catheter

Reliable vascular access is an essential feature of modern day health care. The variety and numbers of intravascular devices (IVDs) used for vascular access in the US health care system have increased greatly during the past 30 years. For example, the use of short-term central venous catheters (CVCs) of all types, such as the conventional noncuffed and nontunneled triple-lumen catheter, the pulmonary artery (PA) catheter, and the short-term percutaneously inserted noncuffed hemodialysis catheter, and arterial catheters for hemodynamic monitoring is now ubiquitous in modern day intensive care units (ICUs). On the other hand, there has been a substantial increase in the use of IVDs for stable long-term or indefinite vascular access, not only in the hospital but also increasingly in the outpatient setting, such as surgically implanted cuffed and tunneled CVCs, central venous ports, and peripherally inserted central venous catheters (PICCs). These devices are used for a wide range of indications, extending far beyond fluid and transfusion therapy, including total parenteral nutrition, chemotherapy, home antibiotic therapy, and, increasingly, chronic outpatient hemodialysis.¹ During the past decade, medicated CVCs with anti-infective surface activity have also come into clinical use.

Unfortunately, the use of devices for vascular access is associated with an underappreciated risk of IVD-related bloodstream infection (BSI), caused by microorganisms that colonize the implanted device or contaminate the fluid pathway at the time of insertion or during its use.²⁻¹⁴ Intravascular devices are now the single most important cause of health care-associated BSI,^{3,4,10,11,14} with an estimated 250,000 to 500,000 IVD-related BSIs occurring each year throughout the United States.^{6,14} Although there has been

[For editorial comment, see page 1151](#)

From the Section of Infectious Diseases, Department of Medicine, University of Wisconsin Medical School and the Infection Control Department, University of Wisconsin Hospital and Clinics, Madison.

Supported by an unrestricted gift for research from the Oscar Rennebohm Foundation of Madison, Wis.

Individual reprints of this article are not available. Address correspondence to Dennis G. Maki, MD, H5/574, University of Wisconsin Hospital and Clinics, Madison, WI 57392 (e-mail: dgmaki@medicine.wisc.edu).

© 2006 Mayo Foundation for Medical Education and Research

recent dispute whether IVD-related BSIs are associated with true attributable mortality,¹⁵⁻¹⁸ there is universal agreement that IVD-related BSIs are associated with increased hospital length of stay, from 10 to 20 days, and excess health care costs, ranging from \$4000 to \$56,000 per episode.¹⁴⁻¹⁸

It is generally acknowledged that the various types of IVDs in use today pose disparate risks of IVD-related BSI²⁻⁸; however, the magnitude of this variability is largely unknown. We report a systematic analysis of published prospective studies of infection associated with the various types of IVDs in adults to determine the relative risks of IVD-related BSI, which can be used for decision making in the selection of IVDs and for benchmarking.

METHODS

SOURCES OF DATA

English-language reports of prospective studies of adults published between January 1, 1966, and July 1, 2005, were identified by MEDLINE search using the following general search strategy: bacteremia [Medical Subject Heading, MeSH] OR septicemia [MeSH] OR bloodstream infection AND the specific type of intravascular device (eg, central venous port). Additional studies of relevance were identified by reviewing the citations of reviews of IVD-related BSI published since 1973.²⁻¹⁴ The following criteria were required for a study to be included in this analysis: (1) the exact type of device studied was described; (2) all data on IVD-related BSI were collected prospectively; (3) the criteria used for determining the presence of IVD-related BSI were clearly specified; (4) the study, at the minimum, used criteria consonant with those of the Centers for Disease Control and Prevention (CDC) and the National Nosocomial Infections Surveillance System¹⁹; and (5) the duration of device implantation in the study population was reported or could be determined from the data provided, permitting quantification of risk.

SUBGROUP ANALYSES

Given the variation in the criteria used to define IVD-related BSI in the studies reviewed, subgroup analyses of studies, stratified by the rigor of the criteria used, were undertaken.

For short-term percutaneously inserted devices, outcomes for 3 subgroups were compared: (1) all studies, including those that met only the most minimal CDC criteria (ie, primary BSI with an IVD in place, *vis-à-vis*, BSI without a plausible identifiable source other than the IVD); (2) studies in which an assessment of IVD-related BSI required microbial concordance between a culture of a segment of the removed catheter and a separate percutane-

ously drawn blood culture but the study protocol did not require culturing of removed devices in the study population unless there was clinical suspicion of infection; and (3) studies in which *all* the study cohort's devices were removed and cultured for evidence of colonization *and* criteria for IVD-related BSI required microbial concordance between a culture of the removed device and a separate percutaneously drawn blood culture.²⁰

For long-term, surgically implanted IVDs, outcomes of 2 subgroups were analyzed: (1) all studies, including those that met minimal CDC criteria; and (2) studies in which the definition of IVD-related BSI required microbial concordance between a culture of the removed device and a separate percutaneously drawn blood culture *or* a 5-fold or greater differential quantitative positivity between paired quantitative blood cultures drawn from the IVD and from a peripheral vein *or* a quantitative blood culture from the device grew more than 1000 colony-forming units.²⁰

STATISTICAL ANALYSES

Best estimates of the risk of IVD-related BSI for each type of IVD—the point incidence with 95% confidence intervals—were calculated from the pooled rates of all studies that met inclusion criteria. Because there was considerable range in the sample sizes of the study populations, each study was weighted by its relative sample size in the IVD group. The resulting rates are identical to those that would be obtained by weighting studies by the inverse of their variance, assuming a common variance within IVD type.

These data satisfy the distributional assumptions for a Poisson distribution, a 1-parameter model in which the statistical mean and variance are identical, which is commonly used to model such data.²¹ Because the pooled rate is identical to the weighted mean, the data are reported in terms of the pooled rate for all studies of each device and expressed per 100 devices and per 1000 device-days, with 95% confidence intervals calculated using Microsoft Excel v.X for Macintosh (Microsoft Inc, Redmond, Wash) and SAS 8.2 (SAS Institute Inc, Cary, NC).

RESULTS

Two hundred studies that prospectively examined the risk of IVD-related BSI with peripheral intravenous (IV) catheters and steel needles,²²⁻³² midline catheters,³³⁻³⁵ arterial catheters for hemodynamic monitoring,³⁶⁻⁴⁹ PA catheters,^{37,50-61} PICCs,^{35,62-75} nonmedicated CVCs,^{33,37,44-46,49,54,63,76-148} medicated CVCs,^{44,105-107,111-114,116,117,121-123,130,133,136,139-141,144,145,147-150} short-term noncuffed and nontunneled hemodialysis CVCs,^{126,151-165} long-term cuffed and tunneled hemodialysis catheters,¹⁶⁵⁻¹⁸⁰ cuffed and tunneled all-purpose Hickman-

TABLE 1. Features of Patients Studied With Short-term Intravascular Devices*

Catheter type	No. of studies by patient care unit and/or patient characteristics						
	ICU	Medical	Surgical/ trauma	Hematology/ oncology	AIDS	TPN	Acute renal failure
Peripheral IV catheters							
Plastic catheters	2	7	7	4
Steel needles	1
Venous cutdown	1
Midline catheters	1	1	2	1	...	2	...
Arterial catheters for hemodynamic monitoring	15	6	11	1
Peripherally inserted central venous catheters	3	3	2	2	1	2	...
Central venous catheters							
Nonmedicated							
Nontunneled	44	32	47	23	6	19	...
Tunneled	2	2	3	3	1	3	...
Medicated							
Chlorhexidine-silver- sulfadiazine	11	5	11	5	...	6	...
Minocycline-rifampin	2	1	1	2	...	1	...
Silver	1	...	2	2
Silver iontophoretic	...	2	2
Benzalkonium chloride	...	1	...	1
Hemodialysis catheters							
Noncuffed and nontunneled	15
Cuffed and tunneled	...	1	2	26	6	8	...
Subcutaneous central ports							
Central	1	14	3
Peripheral	2	1
Intra-aortic balloon pumps	1	1
Left ventricular assist devices	3	3	3

*AIDS = acquired immunodeficiency syndrome; ICU = intensive care unit; IV = intravenous; TPN = total parenteral nutrition.

like CVCs,^{35,128,181-207} central venous ports,^{35,191,197,199,201,207-215} peripheral subcutaneous central venous ports,^{207,216,217} left ventricular assist devices,²¹⁸⁻²²⁰ and intra-aortic balloon pumps²²¹ fulfilled criteria for inclusion in this systematic review. The patient populations in the studies included in the analysis are shown in Tables 1 and 2.

It can be seen that, when risk is expressed as BSIs per 100 devices (Table 3), the highest rates of infection were with percutaneous left ventricular assist devices (26.1%), surgically implanted cuffed and tunneled all-purpose CVCs (22.5%), and cuffed and tunneled hemodialysis catheters (21.2%). Rates were considerably lower with

TABLE 2. Features of Patients Studied With Long-term Intravascular Devices*

Catheter type	No. of studies by outpatient use and/or patient characteristics				
	TPN	Hematology/ oncology	AIDS	Anti-infective therapy	Chronic renal failure
Midline catheters	...	1	...	1	...
Peripherally inserted central venous catheters	4	6	4	1	...
Central venous catheters					
Nonmedicated, nontunneled	1	4
Nonmedicated, tunneled	...	1
Hemodialysis catheters					
Noncuffed, nontunneled	9
Long-term cuffed and tunneled	15
Cuffed and tunneled all-purpose central venous catheters	7	19	3
Subcutaneous central ports					
Central	1	12	1
Peripheral	...	2	1

*AIDS = acquired immunodeficiency syndrome; TPN = total parenteral nutrition.

TABLE 3. Rates of Intravascular Device-Related Bloodstream Infection Caused by Various Types of Devices Used for Vascular Access*

Device	No. of studies	No. of catheters	No. of IVD (d)	No. of BSIs	Rates of IVD-related bloodstream infection			
					Per 100 devices		Per 1000 IVD-days	
					Pooled mean	95% CI	Pooled mean	95% CI
Peripheral IV catheters								
Plastic catheters	110	10,910	28,720	13	0.1	0.1-0.2	0.5	0.2-0.7
Steel needles	1	148	350	3	2.0	0.0-4.3	8.6	0.0-18.2
Venous cutdown	1	27	111	1	3.7	0.0-10.8	9.0	0.0-26.6
Midline catheters	3	514	9251	2	0.4	0.0-0.9	0.2	0.0-0.5
Arterial catheters for hemodynamic monitoring	14	4366	21,397	37	0.8	0.6-1.1	1.7	1.2-2.3
Peripherally inserted central catheters								
Inpatient and outpatient	15	3566	105,839	112	3.1	2.6-3.7	1.1	0.9-1.3
Inpatient	6	625	7137	15	2.4	1.2-3.6	2.1	1.0-3.2
Outpatient	9	2813	98,702	97	3.5	2.8-4.1	1.0	0.8-1.2
Short-term noncuffed central venous catheters								
Nonmedicated								
Nontunneled	79	20,226	322,283	883	4.4	4.1-4.6	2.7	2.6-2.9
Tunneled	9	741	20,065	35	4.7	3.2-6.2	1.7	1.2-2.3
Medicated								
Chlorhexidine-silver-sulfadiazine	18	3367	54,054	89	2.6	2.1-3.2	1.6	1.3-2.0
Minocycline-rifampin	3	690	5797	7	1.0	0.3-1.8	1.2	0.3-2.1
Silver impregnated	2	154	1689	8	5.2	1.7-8.7	4.7	1.5-8.0
Silver iontophoretic	2	396	4796	16	4.0	2.1-6.0	3.3	1.7-5.0
Benzalkonium chloride	1	277	2493	12	4.3	1.9-6.7	4.8	2.1-7.5
Pulmonary artery catheters	13	2057	8143	30	1.5	0.9-2.0	3.7	2.4-5.0
Hemodialysis catheters								
Temporary, noncuffed	16	3066	51,840	246	8.0	7.0-9.0	4.8	4.2-5.3
Long-term, cuffed and tunneled	16	2806	373,563	596	21.2	19.7-22.8	1.6	1.5-1.7
Cuffed and tunneled central venous catheters	29	4512	622,535	1013	22.5	21.2-23.7	1.6	1.5-1.7
Subcutaneous venous ports								
Central	14	3007	983,480	81	3.6	2.9-4.3	0.1	0.0-0.1
Peripheral	3	579	162,203	23	4.0	2.4-5.6	0.1	0.1-0.2
Intra-aortic balloon pumps	1	101	414	3	3.0	0.0-6.3	7.3	0.0-15.4
Left ventricular assist devices	3	157	19,653	41	26.1	19.2-33.0	2.1	1.5-2.7

*BSI = bloodstream infection; CI = confidence interval; IV = intravenous; IVD = intravascular device.

temporary noncuffed hemodialysis catheters (8.0%), silver-impregnated CVCs (5.2%), noncuffed but tunneled CVCs (4.7%), noncuffed and nontunneled CVCs (4.4%), benzalkonium chloride-coated CVCs (4.3%), silver iontophoretic CVCs (4.0%), peripheral subcutaneous central venous ports (4.0%), central venous ports (3.6%), outpatient PICCs (3.5%), intra-aortic balloon pumps (3.0%), chlorhexidine-silver-sulfadiazine-impregnated CVCs (2.6%), inpatient PICCs (2.4%), PA catheters (1.5%), minocycline-rifampin-impregnated CVCs (1.0%), arterial catheters (0.8%), midline catheters (0.4%), and peripheral IV catheters (0.1%).

In contrast, when risk is expressed as BSIs per 1000 IVD-days (Table 3), the level of risk differed, often substantially. The highest rates of IVD-related BSI occurred with peripheral IV catheters placed by surgical cutdown

(9.0 per 1000 IVD-days), peripheral steel needles (8.6), intra-aortic balloon pumps (7.3), benzalkonium chloride-coated CVCs (4.8), short-term noncuffed hemodialysis catheters (4.8), silver-impregnated CVCs (4.7), PA catheters (3.7), and silver iontophoretic CVCs (3.3); rates were considerably lower with noncuffed, nontunneled multilumen CVCs (2.7), inpatient PICCs (2.1), left ventricular assist devices (2.1), tunneled but noncuffed CVCs (1.7), arterial catheters (1.7), chlorhexidine-silver-sulfadiazine-impregnated CVCs (1.6), cuffed and tunneled all-purpose Hickman-like CVCs (1.6), long-term cuffed and tunneled hemodialysis CVCs (1.6), minocycline-rifampin-impregnated CVCs (1.2), outpatient PICCs (1.0), peripheral IV catheters (0.5), peripheral central venous subcutaneous ports (0.1), and central venous ports (0.1).

TABLE 4. Subgroup Analyses of Studies of Short-term Intravascular Devices*

Device	All studies		Studies requiring microbial concordance between catheter and blood cultures		Studies requiring microbial concordance and all devices cultured	
	No. of studies	IVD-related BSIs per 1000 IVD-days (95% CI)	No. of studies	IVD-related BSIs per 1000 IVD-days (95% CI)	No. of studies	IVD-related BSIs per 1000 IVD-days (95% CI)
Peripheral IV catheters	10	0.5 (0.2-0.7)	9	0.6 (0.2-0.9)	9	0.6 (0.2-0.9)
Midline catheters	3	0.2 (0.0-0.5)	2	0.2 (0.0-0.5)	1	0.2 (0.0-0.5)
Arterial catheters for hemodynamic monitoring	14	1.7 (1.2-2.3)	11	1.3 (0.8-1.9)	8	1.4 (0.8-2.0)
Peripherally inserted central catheters	15	1.0 (0.8-1.2)	5	0.8 (0.4-1.3)	4	0.8 (0.4-1.2)
Noncuffed central venous catheters						
Nonmedicated						
Nontunneled	79	2.7 (2.6-2.9)	63	2.9 (2.7-3.2)	50	2.9 (2.6-3.2)
Tunneled	9	1.7 (1.2-2.3)	7	0.9 (0.4-1.3)	5	2.1 (1.0-3.2)
Medicated						
Chlorhexidine-silver-sulfadiazine	18	1.6 (1.3-2.0)	16	1.3 (1.0-1.7)	16	1.3 (1.0-1.7)
Minocycline-rifampin	3	1.2 (0.3-2.1)	3	1.2 (0.3-2.1)	3	1.2 (0.3-2.1)
Pulmonary artery catheters	13	3.7 (2.4-5.0)	11	3.3 (2.0-4.6)	10	3.3 (1.9-4.6)
Noncuffed, nontunneled hemodialysis catheters	16	4.8 (4.2-5.3)	11	5.0 (4.2-5.8)	9	6.1 (4.9-7.4)

*BSI = bloodstream infection; CI = confidence interval; IV = intravenous; IVD = intravascular device.

Risk estimates of IVD-related BSI in the subgroups of studies of short-term devices that used the most rigorous study design and criteria for determination of infection differed little from the overall group of prospective studies of each device, including those fulfilling only minimal CDC criteria (Table 4). With long-term IVDs (Table 5), the pooled estimates of risk of IVD-related BSI with cuffed and tunneled CVCs were approximately 30% lower when studies requiring microbial concordance between a culture of the explanted device and peripheral blood cultures or a differential count greater than 5-fold in paired quantitative blood cultures or more than 1000 colony-forming units of growth from an IVD-drawn quantitative blood culture were analyzed, but the relative level of risk for these device types

among all the IVD types studied remained essentially unchanged.

DISCUSSION

An analysis of this type is inherently limited by the heterogeneity of patient populations, protocols for catheter insertion and site care, and manufacturers' devices used in the studies analyzed. Moreover, the criteria used for defining IVD-related BSI varied across studies, although all the studies met published and widely accepted definitions of IVD-related BSI.^{10,19,20} Finally, because of differing degrees of severity of illness, a particular type of device may be associated with a higher risk of infection if used prefer-

TABLE 5. Subgroup Analyses of Studies of Surgically Implanted Long-term Intravascular Devices*

Device	All studies		Studies requiring microbial concordance between IVD and blood cultures <i>or</i> >5-fold differential positivity in paired quantitative blood cultures <i>or</i> >1000 CFU from a catheter-drawn blood culture	
	No. of studies	IVD-related BSIs per 1000 IVD-days (95% CI)	No. of studies	IVD-related BSIs per 1000 IVD-days (95% CI)
Cuffed and tunneled hemodialysis catheters	16	1.6 (1.5-1.7)	5	1.2 (1.0-1.4)
Cuffed and tunneled central venous catheters	29	1.6 (1.5-1.7)	12	1.1 (1.0-1.2)
Central venous ports	14	0.1 (0.0-0.1)	2	0.1 (0.0-0.1)

*BSI = bloodstream infection; CFU = colony-forming unit; CI = confidence interval; IVD = intravascular device.

entially in a more critically ill or vulnerable patient population. We were unable to adjust for these confounding factors since most of the studies did not provide sufficient data to perform an assessment of severity of illness or comorbid illnesses across all the included studies. However, the subgroup analyses of studies using the most rigorous criteria for determination of infection did not differ materially from the overall study population, which included studies using the most minimal CDC criteria (Tables 4 and 5). Given these limitations, we believe it is important to be cautious about making formal comparisons of risk between different types of devices except when they appear to have been studied in similar patient populations. The primary purpose of our review is to point out that *all* types of IVDs pose significant but often widely differing risks of IVD-related BSI.

Despite these limitations, we believe these data in adults, and similar data we have analyzed in children,²²² provide a useful database that defines relative and representative risks of IVD-related BSI with the various types of devices in use at the present time. Within hospitals, rates of nosocomial BSI are based on clinical surveillance of nosocomial infections.^{4,19,223} We believe that clinical surveillance data in general overestimate the true risk of catheter-related BSI with CVCs while underestimating the actual risk of IVD-related BSI with other types of IVDs because each device in use in the hospital during the surveillance period is not routinely scrutinized, as occurs in a prospective research study of IVD-related infection. Thus, we believe that our analysis defines *upper-level* benchmarks for representative rates of device-related BSI for all types of IVDs.

In most hospitals, as now recommended by the CDC,^{4,12,19,224} the Joint Commission on Accreditation of Healthcare Organizations,²²⁵ and the Agency for Healthcare Research and Quality,²²⁶ risk of CVC-related BSI is expressed as catheter-associated BSIs per 1000 CVC-days; in essence, all health care-associated BSIs that cannot reasonably be linked to a site of local infection are attributed to the patient's CVC. The implication of this practice, as noted, is that the true risk of CVC-related BSI is usually overestimated because some BSIs are actually *secondary* BSIs deriving from unrecognized sites of local infection, such as an intra-abdominal abscess, nosocomial pneumonia, or urinary tract infection; moreover, in granulocytopenic and other severely immunocompromised patients, primary BSIs may occasionally derive from microbial translocation,^{227,228} also unrelated to a CVC. Finally, as noted, concomitant use of other IVDs, such as arterial catheters in an ICU—which are underappreciated for their potential to cause catheter-related BSI—further inflates estimates of the risk of CVC-related BSI. We believe that

hospitals conducting surveillance for benchmarking and to assess intramural trends and progress would be better served to also report their rates of BSI *originating from* IVDs as IVD-related BSIs per 1000 device-days, particularly with central venous devices. This can be easily accomplished using the more rigorous diagnostic methods and criteria for IVD-related BSI used by most of the studies analyzed in this review.^{10,20}

For many years, the risk of nosocomial BSI originating from an IVD was expressed solely by IVD-related BSIs per 100 devices, *vis-à-vis*, the percentage of devices studied.²⁻⁶ However, in recent years, as now widely recommended,²²³⁻²²⁶ US hospitals have been calculating and reporting rates, particularly with CVCs, as BSIs per 1000 catheter-days. Our analysis provides the first rigorous data to support this practice. As shown in Table 3, cuffed and tunneled CVCs appear to be far more hazardous (22.5% risk of catheter-related BSI) than short-term nonmedicated, noncuffed, and nontunneled CVCs (4.4%); PICCs used in outpatients (3.5%), mainly for home antimicrobial therapy, appear to be more hazardous than PICCs used in inpatients (2.4%). However, when risk is expressed per 1000 catheter-days, cuffed and tunneled all-purpose CVCs, used primarily for long-term access in patients with leukemia, bone marrow transplant recipients, and other immunocompromised patients, pose only half the risk of catheter-related BSI (1.6 per 1000 IVD-days) over time as noncuffed and nontunneled multilumen CVCs (2.7 per 1000 IVD-days), used most often in immunocompetent patients in an ICU. When used in inpatients, PICCs cause considerably more catheter-related BSIs (2.1 per 1000 catheter-days) than when used in outpatients (1.0 per 1000 catheter-days). Similarly, in the ICU, short-term noncuffed multilumen CVCs might appear to be considerably more hazardous (4.4%) than PA catheters (1.5%); however, when rates are expressed per 1000 catheter-days, PA catheters (3.7 per 1000 catheter-days) actually pose higher risks of catheter-related BSI than noncuffed multilumen CVCs (2.7 per 1000 catheter-days).

Arterial catheters, which permit continuous blood pressure monitoring and ready access for blood specimens, especially for arterial blood gas measurements, are used in more than 6 million patients in US hospitals each year.^{6,14} The CDC does not advocate surveillance of arterial catheter-related BSIs,^{12,224} and many clinicians consider arterial catheters to pose little risk of catheter-related BSI, in contrast to their patients' CVCs, and do not regularly culture arterial catheters in patients suspected of line sepsis. Our analysis suggests that this practice is not justified (Table 3). Arterial catheters are among the most heavily manipulated catheters in the ICU or the operating room and, as a result, the risk of arterial catheter-related BSI (1.7 per 1000 cath-

eter-days) is close to that seen with short-term nonmedicated, noncuffed, and nontunneled multilumen CVCs (2.7 per 1000 catheter-days). Novel technologies for prevention of infection, which have shown efficacy with CVCs,²²⁹ deserve to be studied and applied with arterial catheters.

Many clinicians believe that PICCs are much safer for intermediate-term access than conventional percutaneously inserted noncuffed CVCs placed in the subclavian or internal jugular vein, probably because most of the earlier studies of PICCs were conducted in outpatients in whom PICCs are used primarily for home IV antimicrobial therapy. The results of the current analysis suggest that PICCs used in inpatients (2.1 per 1000 catheter-days) pose a slightly lower risk of catheter-related BSI than standard noncuffed and nonmedicated CVCs placed in the subclavian or internal jugular vein (2.7 BSIs per 1000 catheter-days). This may well derive from the considerably lower levels of cutaneous colonization on the arms vs the base of the neck, the upper anterior area of the chest, or the groin,²³⁰ although we caution against a wholesale conversion to PICCs in the inpatient setting. A large prospective study by Safdar and Maki⁷⁵ found that PICCs used exclusively in the inpatient setting (3.5 BSIs per 1000 catheter-days) posed risks of catheter-related BSI at least as high as those seen with noncuffed and nontunneled CVCs (2.7 BSIs per 1000 IVD-days) and considerably higher than with cuffed and tunneled all-purpose Hickman-like CVCs (1.6 BSIs per 1000 catheter-days). These findings suggest that the role for PICCs in hospitalized patients warrants greater scrutiny, and randomized trials comparing PICCs with noncuffed short-term CVCs, especially in the ICU, or with cuffed and tunneled CVCs in patients with malignancy who require longer-term central access are needed.³³

An estimated 500,000 patients require temporary hemodialysis each year because of the occurrence of acute renal failure.²³¹ These patients are now widely managed with noncuffed, percutaneously inserted, double-lumen hemodialysis catheters, most commonly placed in the internal jugular vein.¹ Our analysis shows that the use of noncuffed hemodialysis catheters is associated with a substantial risk of infection (4.8 BSIs per 1000 catheter-days). Placing a cuffed and tunneled hemodialysis catheter greatly reduces the risk of catheter-related BSI (1.6 per 1000 catheter-days). It must be questioned why noncuffed hemodialysis catheters are used at all, beyond an occasional unstable patient who requires urgent pheresis at night or on weekends or who has bacteremic sepsis and requires urgent hemodialysis; when the infection has been controlled in the latter circumstance, a cuffed and tunneled hemodialysis catheter should be placed to reduce the risk of catheter-related BSI during the necessary period of hemodialysis.

For long-term central venous access, these data show that surgically implanted central and peripheral venous ports pose far less risk than cuffed and tunneled catheters (0.1 vs 1.6 BSIs per 1000 IVD-days), a finding that is consonant with a large prospective observational study of complications with both types of devices.¹⁹⁷ However, it must be cautioned that clinicians making decisions on types of devices to use for long-term access should recognize that, if the patient will need continuous access for many days or intermittent access day after day, a cuffed and tunneled catheter is preferable to a subcutaneous central port,^{12,14} which becomes much more vulnerable to becoming infected if accessed repeatedly or continuously for prolonged periods.

For intermediate-term central access, such as in patients in an ICU, this analysis suggests that tunneling a noncuffed CVC reduces the risk of CVC-related BSI by 33% (1.7 vs 2.7 per 1000 IVD-days), a finding consistent with a recent meta-analysis.²³² However, the added time and effort to tunnel a noncuffed CVC, particularly in patients who may be coagulopathic and vulnerable to excessive bleeding, has limited the practice of tunneling noncuffed standard CVCs in most US ICUs. The use of novel technology, such as CVCs with anti-infective surfaces^{44,105-107,111-114,116,117,121-123,130,133,136,139-141,144,145,147-150} (Table 3) and chlorhexidine-impregnated site dressings,²³³ is more simple and at least as effective at reducing the risk of CVC-related BSI²²⁹ and can obviate the need to tunnel a CVC catheter as an infection control strategy.

Updated evidence-based recommendations for prevention of IVD-related BSI were published in 2002 by an expert panel convened by the CDC's Hospital Infection Control Practices Advisory Committee.¹² This guideline provides state-of-the-art recommendations, each scored by the quality of the underlying scientific evidence, ranging from consensus theoretical rationale to well-designed prospective, randomized clinical trials, and covers all aspects of IVD care, both in adults and children. Consistent application of these recommendations, especially if buttressed by the preventive technologies,²²⁹ can greatly reduce the risk of IVD-related BSI.²²⁴ Over the past decade, hospitals that have taken a highly organized, multidisciplinary systems approach that starts with formal training of all ICU personnel who insert and care for noncuffed CVCs and focuses on limiting femoral site insertions, routine use of maximal sterile barriers during catheter insertion, disinfection of insertion sites with tincture of chlorhexidine rather than iodine-based antiseptics, and prompt removal of unneeded catheters have reported striking reductions in the incidence of CVC-associated BSI within their ICUs.²³⁴⁻²³⁸ However, these programs have focused on a small fraction of hospitalized patients with IVDs, those in an ICU with

short-term noncuffed CVCs. The median incidence of CVC-associated BSI in the medical-surgical ICUs of the hospitals of CDC's National Nosocomial Infection Surveillance System study between 1992 and 2002 was nearly 5 cases per 1000 catheter-days,²²³ and it is clear that quality improvement programs aimed to make vascular access as safe as possible must address all forms of vascular access and all types of IVDs, not only devices used throughout the hospital but also those used in the outpatient setting, where up to 2 million persons in the United States have an implanted IVD that is used daily or intermittently.^{14,239} This systematic review can provide a database on which institutional quality improvement efforts can benchmark and against which studies of preventive strategies can be assessed.

CONCLUSIONS

These data, based on prospective studies in which every IVD was analyzed for evidence of infection using microbiologically based criteria, show that *all* types of IVDs pose a risk of IVD-related BSI and can be used for benchmarking rates of infection caused by various types of IVDs in use at the present time. Expressing risk of IVD-related BSI per 1000 IVD-days allows for more meaningful estimates of risk than measuring BSIs per 100 IVDs. Since almost all the national effort to date to reduce the risk of IVD-related infection has focused on short-term CVCs used in ICUs, we believe that infection control programs must begin to strive to consistently apply essential control measures and preventive technologies with *all* types of IVDs.

*We are grateful to Richard Holcombe, PhD, for expert statistical guidance and assistance. This analysis of studies done in adults complements a similar analysis of studies done in children.*²²²

REFERENCES

1. US Renal Data System. Excerpts from the USRDS annual data report: atlas of end-stage renal disease in the United States: clinical indicators of care. *Am J Kidney Dis*. 2001;4(suppl 3):S79-S90.
2. Maki DG, Goldman DA, Rhame FS. Infection control in intravenous therapy. *Ann Intern Med*. 1973;79:867-887.
3. Maki DG. Nosocomial bacteremia: an epidemiologic overview. *Am J Med*. 1981;70:719-732.
4. Banerjee SN, Emori TG, Culver DH, et al. National Nosocomial Infections Surveillance System. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. *Am J Med*. 1991;91:86S-89S.
5. Collignon PJ, the Australian Study on Intravascular Catheter Associated Sepsis. Intravascular catheter associated sepsis: a common problem. *Med J Aust*. 1994;161:374-378.
6. Maki DG. Infections caused by intravascular devices used in infusion therapy: pathogenesis, prevention, and management. In: Bisno AL, Waldvogel FA, eds. *Infections Associated With Indwelling Medical Devices*. 2nd ed. Washington, DC: ASM Press; 1994:155-212.
7. Maki D, Mermel L. Infections due to infusion therapy. In: Bennett JV, Brachman PS, eds. *Hospital Infections*. 4th ed. Philadelphia, Pa: Lippincott-Raven; 1998:689-724.
8. Raad I. Intravascular-catheter-related infections. *Lancet*. 1998;351:893-898.
9. Mermel LA. Prevention of intravascular catheter-related infections [published correction appears in *Ann Intern Med*. 2000;133:5]. *Ann Intern Med*. 2000;132:391-402.
10. Crnich CJ, Maki DG. The role of intravascular devices in sepsis. *Curr Infect Dis Rep*. 2001;3:496-506.
11. Maki DG, Crnich CJ. Line sepsis in the ICU: prevention, diagnosis, and management. *Semin Respir Crit Care Med*. 2003;24:23-36.
12. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis*. 2002;35:1281-1307.
13. Raad II, Hanna HA. Intravascular catheter-related infections: new horizons and recent advances. *Arch Intern Med*. 2002;162:871-878.
14. Crnich CJ, Maki DG. Infections caused by intravascular devices: epidemiology, pathogenesis, diagnosis, prevention, and treatment. In: *APIC Text of Infection Control and Epidemiology*. Vol 1. 2nd ed. Washington, DC: Association for Professionals in Infection Control and Epidemiology, Inc; 2005:24.21-24.26.
15. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. *JAMA*. 1994;271:1598-1601.
16. Renaud B, Brun-Buisson C, ICU-Bacteremia Study Group. Outcomes of primary and catheter-related bacteremia: a cohort and case-control study in critically ill patients. *Am J Respir Crit Care Med*. 2001;163:1584-1590.
17. Orsi GB, Di Stefano L, Noah N. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs. *Infect Control Hosp Epidemiol*. 2002;23:190-197.
18. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. *Clin Infect Dis*. 2005 Dec 1;41:1591-1598. Epub 2005 Oct 25.
19. Gaynes RP, Horan TC. Surveillance of nosocomial infections. In: Mayhall CG, ed. *Hospital Epidemiology and Infection Control*. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:1285-1317.
20. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection [published correction appears in *Ann Intern Med*. 2005;142:803]. *Ann Intern Med*. 2005;142:451-466.
21. Box GEP, Hunter WG, Hunter JS. *Statistics for Experimenters: An Introduction to Design, Data Analysis, and Model Building*. New York, NY: John Wiley & Sons; 1978.
22. Bolansky BL, Shepard GH, Scott HW Jr. The hazards of intravenous polyethylene catheters in surgical patients. *Surg Gynecol Obstet*. 1970;130:342-346.
23. Tager IB, Ginsberg MB, Ellis SE, et al. An epidemiologic study of the risks associated with peripheral intravenous catheters. *Am J Epidemiol*. 1983;118:839-851.
24. Gantz NM, Presswood GM, Goldberg R, Doern G. Effects of dressing type and change interval on intravenous therapy complication rates. *Diagn Microbiol Infect Dis*. 1984;2:325-332.
25. Maki DG, Ringer M. Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters: gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing. *JAMA*. 1987;258:2396-2403.
26. Richet H, Hubert B, Nitemberg G. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. *J Clin Microbiol*. 1990;28:2520-2525.
27. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters: a randomized controlled trial. *Ann Intern Med*. 1991;114:845-854.
28. Sherertz RJ, Stephens JL, Marosok RD, et al. The risk of peripheral vein phlebitis associated with chlorhexidine-coated catheters: a randomized double-blind trial. *Infect Control Hosp Epidemiol*. 1997;18:230-236.
29. Bregenzler T, Conen D, Sakmann P, Widmer AF. Is routine replacement of peripheral intravenous catheters necessary? *Arch Intern Med*. 1998;158:151-156.
30. Cornely OA, Bethe U, Pauls R, Waldschmidt D. Peripheral Teflon catheters: factors determining incidence of phlebitis and duration of cannulation. *Infect Control Hosp Epidemiol*. 2002;23:249-253.
31. Creamer E, McCarthy G, Tighe I, Smyth E. A survey of nurses' assessment of peripheral intravenous catheters. *Br J Nurs*. 2002;11:999-1000, 1002, 1004-1006.

32. Band JD, Maki DG. Steel needles used for intravenous therapy: morbidity in patients with hematologic malignancy. *Arch Intern Med.* 1980;140:31-34.
33. Kohlhardt SR, Smith RC, Wright CR. Peripheral versus central intravenous nutrition: comparison of two delivery systems. *Br J Surg.* 1994;81:66-70.
34. Goetz AM, Miller J, Wagener MM, Muder RR. Complications related to intravenous midline catheter usage: a 2-year study. *J Intraven Nurs.* 1998;21:76-80.
35. Tokars JI, Cookson ST, McArthur MA, Boyer CL, McGeer AJ, Jarvis WR. Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy. *Ann Intern Med.* 1999;131:340-347.
36. Band JD, Maki DG. Infections caused by arterial catheters used for hemodynamic monitoring. *Am J Med.* 1979;67:735-741.
37. Pinilla JC, Ross DF, Martin T, Crump H. Study of the incidence of intravascular catheter infection and associated septicemia in critically ill patients. *Crit Care Med.* 1983;11:21-25.
38. Russell JA, Joel M, Hudson RJ, Mangano DT, Schlobohm RM. Prospective evaluation of radial and femoral artery catheterization sites in critically ill adults. *Crit Care Med.* 1983;11:936-939.
39. Thomas F, Orme JF Jr, Clemmer TP, Burke JP, Elliott CG, Gardner RM. A prospective comparison of arterial catheter blood and catheter-tip cultures in critically ill patients. *Crit Care Med.* 1984;12:860-862.
40. Damen J. The microbiological risk of invasive hemodynamic monitoring in adults undergoing cardiac valve replacement. *J Clin Monit.* 1986;2:87-94.
41. Naguib M, Hassan M, Farag H, Bodman RI, Absood GH. Cannulation of the radial and dorsalis pedis arteries. *Br J Anaesth.* 1987;59:482-488.
42. Norwood SH, Cormier B, McMahon NG, Moss A, Moore V. Prospective study of catheter-related infection during prolonged arterial catheterization. *Crit Care Med.* 1988;16:836-839.
43. Leroy O, Billiau V, Beuscart C, et al. Nosocomial infections associated with long-term radial artery cannulation. *Intensive Care Med.* 1989;15:241-246.
44. Kamal GD, Pfaller MA, Rempe LE, Jebson PJ. Reduced intravascular catheter infection by antibiotic bonding: a prospective, randomized, controlled trial. *JAMA.* 1991;265:2364-2368.
45. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. *Lancet.* 1991;338:339-343.
46. Mimoz O, Pieroni L, Lawrence C, et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. *Crit Care Med.* 1996;24:1818-1823.
47. Safdar N, Maki DG. The incidence and pathogenesis of catheter-related bloodstream infection with arterial catheters [abstract]. *Abstr Intersci Conf Antimicrob Agents Chemother.* 2002;42:299. Abstract K-81.
48. Rijnders BJ, Van Wijngaerden E, Wilmer A, Peetermans WE. Use of full sterile barrier precautions during insertion of arterial catheters: a randomized trial. *Clin Infect Dis.* 2003 Mar 15;36:743-748. Epub 2003 Feb 27.
49. Lorente L, Villegas J, Martin MM, Jimenez A, Mora ML. Catheter-related infection in critically ill patients. *Intensive Care Med.* 2004 Aug;30:1681-1684. Epub 2004 May 25.
50. Elliott CG, Zimmerman GA, Clemmer TP. Complications of pulmonary artery catheterization in the care of critically ill patients: a prospective study. *Chest.* 1979;76:647-652.
51. Groeger J, Carlon GC, Howland WS. Contamination shields for pulmonary artery catheters [abstract]. *Crit Care Med.* 1983;11:230.
52. Hudson-Civetta JA, Civetta JM, Martinez OV, Hoffman TA. Risk and detection of pulmonary artery catheter-related infection in septic surgical patients. *Crit Care Med.* 1987;15:29-34.
53. Senagore A, Waller JD, Bonnell BW, Bursch LR, Scholten DJ. Pulmonary artery catheterization: a prospective study of internal jugular and subclavian approaches. *Crit Care Med.* 1987;15:35-37.
54. Horowitz HW, Dworkin BM, Savino JA, Byrne DW, Pecora NA. Central catheter-related infections: comparison of pulmonary artery catheters and triple lumen catheters for the delivery of hyperalimentation in a critical care setting. *JPEN J Parenter Enteral Nutr.* 1990;14:588-592.
55. Mermel LA, McCormick RD, Springman SR, Maki DG. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping. *Am J Med.* 1991;91:197S-205S.
56. Rello J, Coll P, Net A, Prats G. Infection of pulmonary artery catheters: epidemiologic characteristics and multivariate analysis of risk factors. *Chest.* 1993;103:132-136.
57. Maki DG, Stolz SS, Wheeler S, Mermel LA. A prospective, randomized trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: implications for catheter management. *Crit Care Med.* 1994;22:1729-1737.
58. Cohen Y, Fosse JP, Karoubi P, et al. The "hands-off" catheter and the prevention of systemic infections associated with pulmonary artery catheter: a prospective study. *Am J Respir Crit Care Med.* 1998;157:284-287.
59. Blot F, Chachaty E, Raynard B, Antoun S, Bourgain JL, Nitenberg G. Mechanisms and risk factors for infection of pulmonary artery catheters and introducer sheaths in cancer patients admitted to an intensive care unit. *J Hosp Infect.* 2001;48:289-297.
60. Kac G, Durain E, Amrein C, Herisson E, Fiemeyer A, Buu-Hoi A. Colonization and infection of pulmonary artery catheter in cardiac surgery patients: epidemiology and multivariate analysis of risk factors. *Crit Care Med.* 2001;29:971-975.
61. Chen YY, Yen DH, Yang YG, Liu CY, Wang FD, Chou P. Comparison between replacement at 4 days and 7 days of the infection rate for pulmonary artery catheters in an intensive care unit. *Crit Care Med.* 2003;31:1353-1358.
62. Abi-Nader JA. Peripherally inserted central venous catheters in critical care patients. *Heart Lung.* 1993;22:428-434.
63. Raad I, Davis S, Becker M, et al. Low infection rate and long durability of nontunneled silastic catheters: a safe and cost-effective alternative for long-term venous access. *Arch Intern Med.* 1993;153:1791-1796.
64. Lam S, Scannell R, Roessler D, Smith MA. Peripherally inserted central catheters in an acute-care hospital. *Arch Intern Med.* 1994;154:1833-1837.
65. Ng PK, Ault MJ, Maldonado LS. Peripherally inserted central catheters in the intensive care unit. *J Intensive Care Med.* 1996;11:49-54.
66. Ng PK, Ault MJ, Ellrodt AG, Maldonado L. Peripherally inserted central catheters in general medicine. *Mayo Clin Proc.* 1997;72:225-233.
67. Duerksen DR, Papineau N, Siemens J, Yaffe C. Peripherally inserted central catheters for parenteral nutrition: a comparison with centrally inserted catheters. *JPEN J Parenter Enteral Nutr.* 1999;23:85-89.
68. Hoffer EK, Borsa J, Santulli P, Bloch R, Fontaine AB. Prospective randomized comparison of valved versus nonvalved peripherally inserted central vein catheters. *AJR Am J Roentgenol.* 1999;173:1393-1398.
69. Fong NI, Holtzman SR, Bettmann MA, Bettis SJ. Peripherally inserted central catheters: outcome as a function of the operator. *J Vasc Interv Radiol.* 2001;12:723-729.
70. Hoffer EK, Bloch RD, Borsa JJ, Santulli P, Fontaine AB, Francoeur N. Peripherally inserted central catheters with distal versus proximal valves: prospective randomized trial. *J Vasc Interv Radiol.* 2001;12:1173-1177.
71. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. *J Clin Oncol.* 2002;20:3276-3281.
72. Yamamoto AJ, Solomon JA, Soulen MC, et al. Sutureless securement device reduces complications of peripherally inserted central venous catheters. *J Vasc Interv Radiol.* 2002;13:77-81.
73. Chlebicki MP, Teo EK. Review of peripherally inserted central catheters in the Singapore acute-care hospital. *Singapore Med J.* 2003;44:531-535.
74. Harter C, Ostendorf T, Bach A, Egerer G, Goldschmidt H, Ho AD. Peripherally inserted central venous catheters for autologous blood progenitor cell transplantation in patients with haematological malignancies. *Support Care Cancer.* 2003 Dec;11:790-794. Epub 2003 Sep 20.
75. Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. *Chest.* 2005;128:489-495.
76. von Meyenfeldt MM, Stapert J, de Jong PC, Soeters PB, Wesdorp RI, Greep JM. TPN catheter sepsis: lack of effect of subcutaneous tunnelling of PVC catheters on sepsis rate. *JPEN J Parenter Enteral Nutr.* 1980;4:514-517.
77. Garden OJ, Sim AJ. A comparison of tunneled and nontunneled subclavian vein catheters: a prospective study of complications during parenteral feeding. *Clin Nutr.* 1983;2:51-54.
78. Sitges-Serra A, Puig P, Linares J, et al. Hub colonization as the initial step in an outbreak of catheter-related sepsis due to coagulase negative staphylococci during parenteral nutrition. *JPEN J Parenter Enteral Nutr.* 1984;8:668-672.
79. Pettigrew RA, Lang SD, Haydock DA, Parry BR, Bremner DA, Hill GL. Catheter-related sepsis in patients on intravenous nutrition: a prospective

study of quantitative catheter cultures and guidewire changes for suspected sepsis. *Br J Surg*. 1985;72:52-55.

80. Andersen PT, Herlevsen P, Schaumburg H. A comparative study of 'Op-site' and 'Nobectan gauze' dressings for central venous line care. *J Hosp Infect*. 1986;7:161-168.

81. Collignon PJ, Soni N, Pearson IY, Woods WP, Munro R, Sorrell TC. Is semiquantitative culture of central vein catheter tips useful in the diagnosis of catheter-associated bacteremia? *J Clin Microbiol*. 1986;24:532-535.

82. Guichard I, Nitenberg G, Abitbol JL, Andreumont A, Leclercq B, Escudier B. Tunneled versus nontunneled catheters for parenteral nutrition (PN) in an intensive care unit: a controlled prospective study of catheter related sepsis (CRS) [abstract]. *Clin Nutr*. 1986;5(suppl):P.139.

83. Kelly CS, Ligas JR, Smith CA, Madden GM, Ross KA, Becker DR. Sepsis due to triple lumen central venous catheters. *Surg Gynecol Obstet*. 1986;163:14-16.

84. Fan ST, Teoh-Chan CH, Lau KF, Chu KW, Kwan AK, Wong KK. Predictive value of surveillance skin and hub cultures in central venous catheters sepsis. *J Hosp Infect*. 1988;12:191-198.

85. Lee RB, Buckner M, Sharp KW. Do multi-lumen catheters increase central venous catheter sepsis compared to single-lumen catheters? *J Trauma*. 1988;28:1472-1475.

86. Maki DG, Cobb L, Garman JK, Shapiro JM, Ringer M, Helgeson RB. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. *Am J Med*. 1988;85:307-314.

87. Yeung C, May J, Hughes R. Infection rate for single lumen v triple lumen subclavian catheters. *Infect Control Hosp Epidemiol*. 1988;9:154-158.

88. de Cicco M, Panarello G, Chiaradia V, et al. Source and route of microbial colonisation of parenteral nutrition catheters. *Lancet*. 1989;2:1258-1261.

89. Flowers RH III, Schwenzler KJ, Kopel RF, Fisch MJ, Tucker SI, Farr BM. Efficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection: a randomized, controlled trial. *JAMA*. 1989;261:878-883.

90. Gil RT, Kruse JA, Thill-Baharozian MC, Carlson RW. Triple- vs single-lumen central venous catheters: a prospective study in a critically ill population. *Arch Intern Med*. 1989;149:1139-1143.

91. Bock SN, Lee RE, Fisher B, et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. *J Clin Oncol*. 1990;8:161-169.

92. Ullman RF, Gurevich I, Schoch PE, Cunha BA. Colonization and bacteremia related to duration of triple-lumen intravascular catheter placement. *Am J Infect Control*. 1990;18:201-207.

93. Bonawitz SC, Hammell EJ, Kirkpatrick JR. Prevention of central venous catheter sepsis: a prospective randomized trial. *Am Surg*. 1991;57:618-623.

94. Murr MM, Rosenquist MD, Lewis RW II, Heinle JA, Kealey GP. A prospective safety study of femoral vein versus nonfemoral vein catheterization in patients with burns. *J Burn Care Rehabil*. 1991;12:576-578.

95. Clark-Christoff N, Watters VA, Sparks W, Snyder P, Grant JP. Use of triple-lumen subclavian catheters for administration of total parenteral nutrition. *JPEN J Parenter Enteral Nutr*. 1992;16:403-407.

96. Farkas JC, Liu N, Blierot JP, Chevret S, Goldstein FW, Carlet J. Single-versus triple-lumen central catheter-related sepsis: a prospective randomized study in a critically ill population. *Am J Med*. 1992;93:277-282.

97. Inoue Y, Nezu R, Matsuda H, et al. Prevention of catheter-related sepsis during parenteral nutrition: effect of a new connection device. *JPEN J Parenter Enteral Nutr*. 1992;16:581-585.

98. Babycos CR, Barocas A, Webb WR. A prospective randomized trial comparing the silver-impregnated collagen cuff with the bedside tunneled subclavian catheter. *JPEN J Parenter Enteral Nutr*. 1993;17:61-63.

99. Savage AP, Picard M, Hopkins CC, Malt RA. Complications and survival of multilumen central venous catheters used for total parenteral nutrition. *Br J Surg*. 1993;80:1287-1290.

100. Wille JC, Blusse van Oud Albas A, Thewessen EA. A comparison of two transparent film-type dressings in central venous therapy. *J Hosp Infect*. 1993;23:113-121.

101. Andrivet P, Bacquer A, Ngoc CV, et al. Lack of clinical benefit from subcutaneous tunnel insertion of central venous catheters in immunocompromised patients. *Clin Infect Dis*. 1994;18:199-206.

102. Moro ML, Vigano EF, Cozzi Lepri A. Central Venous Catheter-Related Infections Study Group. Risk factors for central venous catheter-related infections in surgical and intensive care units [published correction appears in

Infect Control Hosp Epidemiol. 1994;15:508-509]. *Infect Control Hosp Epidemiol*. 1994;15:253-264.

103. Volkow P, Sanchez-Mejorada G, de la Vega SL, et al. Experience of an intravenous therapy team at the Instituto Nacional de Cancerologia (Mexico) with a long-lasting, low-cost silastic venous catheter. *Clin Infect Dis*. 1994;18:719-725.

104. Smith HO, DeVictoria CL, Garfinkel D, et al. A prospective randomized comparison of an attached silver-impregnated cuff to prevent central venous catheter-associated infection. *Gynecol Oncol*. 1995;58:92-100.

105. Bach A, Schmidt H, Bottiger B, et al. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. *J Antimicrob Chemother*. 1996;37:315-322.

106. Ciresi DL, Albrecht RM, Volkers PA, Scholten DJ. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. *Am Surg*. 1996;62:641-646.

107. Pemberton LB, Ross V, Cuddy P, Kremer H, Fessler T, McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters: a prospective randomized trial. *Arch Surg*. 1996;131:986-989.

108. Segura M, Alvarez-Lerma F, Tellado JM, et al. A clinical trial on the prevention of catheter-related sepsis using a new hub model. *Ann Surg*. 1996;223:363-369.

109. Timsit JF, Sebille V, Farkas JC, et al. Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. *JAMA*. 1996;276:1416-1420.

110. Durbec O, Viviani X, Potie F, Violet R, Albanese J, Martin C. A prospective evaluation of the use of femoral venous catheters in critically ill adults. *Crit Care Med*. 1997;25:1986-1989.

111. Logghe C, Van Ossel C, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. *J Hosp Infect*. 1997;37:145-156.

112. Loo S, van Heerden PV, Gollege CL, Roberts BL, Power BM. Infection in central lines: antiseptic-impregnated vs standard non-impregnated catheters. *Anaesth Intensive Care*. 1997;25:637-639.

113. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. *Ann Intern Med*. 1997;127:257-266.

114. Raad I, Darouiche R, Dupuis J, et al. Texas Medical Center Catheter Study Group. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. *Ann Intern Med*. 1997;127:267-274.

115. Tacconelli E, Tumbarello M, Pittiruti M, et al. Central venous catheter-related sepsis in a cohort of 366 hospitalised patients. *Eur J Clin Microbiol Infect Dis*. 1997;16:203-209.

116. Tennenberg S, Lieser M, McCurdy B, et al. A prospective randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. *Arch Surg*. 1997;132:1348-1351.

117. Heard SO, Wagle M, Vijayakumar E, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. *Arch Intern Med*. 1998;158:81-87.

118. Skiest DJ, Grant P, Keiser P. Nontunneled central venous catheters in patients with AIDS are associated with a low infection rate. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998;17:220-226.

119. Martin C, Bruder N, Papazian L, Saux P, Gouin F. Catheter-related infections following axillary vein catheterization. *Acta Anaesthesiol Scand*. 1998;42:52-56.

120. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. *Chest*. 1998;114:207-213.

121. Bach A, Eberhardt H, Frick A, Schmidt H, Bottiger BW, Martin E. Efficacy of silver-coating central venous catheters in reducing bacterial colonization. *Crit Care Med*. 1999;27:515-521.

122. Collin GR. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project. *Chest*. 1999;115:1632-1640.

123. Hannan M, Juste RN, Umasanker S, et al. Antiseptic-bonded central venous catheters and bacterial colonisation. *Anaesthesia*. 1999;54:868-872.

124. McKinley S, Mackenzie A, Finfer S, Ward R, Penfold J. Incidence and predictors of central venous catheter related infection in intensive care patients. *Anaesth Intensive Care*. 1999;27:164-169.

125. Nikolettis S, Leslie G, Gandossi S, Coombs G, Wilson R. A prospective, randomized, controlled trial comparing transparent polyurethane and hydrocolloid dressings for central venous catheters. *Am J Infect Control*. 1999;27:488-496.
126. Souweine B, Traore O, Aublet-Cuvelier B, et al. Dialysis and central venous catheter infections in critically ill patients: results of a prospective study. *Crit Care Med*. 1999;27:2394-2398.
127. Timsit JF, Bruneel F, Cheval C, et al. Use of tunneled femoral catheters to prevent catheter-related infection: a randomized, controlled trial. *Ann Intern Med*. 1999;130:729-735.
128. Petrosillo N, Pugliese G, Girardi E, et al. Gruppo HIV e Infezioni Ospedaliere. Nosocomial infections in HIV infected patients. *AIDS*. 1999;13:599-605.
129. Fortun J, Perez-Molina JA, Asensio A, et al. Semiquantitative culture of subcutaneous segment for conservative diagnosis of intravascular catheter-related infection. *JPEN J Parenter Enteral Nutr*. 2000;24:210-214.
130. Hanley EM, Veeder A, Smith T, Drusano G, Currie E, Venezia RA. Evaluation of an antiseptic triple-lumen catheter in an intensive care unit. *Crit Care Med*. 2000;28:366-370.
131. Humar A, Ostromecki A, Drenfeld J, et al. Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antiseptics for prevention of central venous catheter infection. *Clin Infect Dis*. 2000 Oct;31:1001-1007. Epub 2000 Oct 25.
132. Luna J, Masdeu G, Perez M, et al. Clinical trial evaluating a new hub device designed to prevent catheter-related sepsis. *Eur J Clin Microbiol Infect Dis*. 2000;19:655-662.
133. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. *Diagn Microbiol Infect Dis*. 2000;38:1-5.
134. Tacconelli E, Tumbarello M, de Gaetano Donati K, et al. Morbidity associated with central venous catheter-use in a cohort of 212 hospitalized subjects with HIV infection. *J Hosp Infect*. 2000;44:186-192.
135. Yoo S, Ha M, Choi D, Pai H. Effectiveness of surveillance of central catheter-related bloodstream infection in an ICU in Korea. *Infect Control Hosp Epidemiol*. 2001;22:433-436.
136. Harter C, Salwender HJ, Bach A, Egerer G, Goldschmidt H, Ho AD. Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters. *Cancer*. 2002;94:245-251.
137. Karthaus M, Doellmann T, Klimasch T, Krauter J, Heil G, Ganser A. Central venous catheter infections in patients with acute leukemia. *Chemotherapy*. 2002;48:154-157.
138. Petrosillo N, Viale P, Nicastrì E, et al. Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. *Clin Infect Dis*. 2002 Mar 1;34:677-685. Epub 2002 Jan 25.
139. Bong JJ, Kite P, Wilco MH, McMahon MJ. Prevention of catheter related bloodstream infection by silver iontophoretic central venous catheters: a randomised controlled trial. *J Clin Pathol*. 2003;56:731-735.
140. Ranucci M, Isgro G, Giomarelli PP, et al. Catheter Related Infection Trial (CRIT) Group. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. *Crit Care Med*. 2003;31:52-59.
141. Richards B, Chaboyer W, Bladen T, Schluter PJ. Effect of central venous catheter type on infections: a prospective clinical trial. *J Hosp Infect*. 2003;54:10-17.
142. Volkow P, Vazquez C, Tellez O, et al. Polyurethane II catheter as long-indwelling intravenous catheter in patients with cancer. *Am J Infect Control*. 2003;31:392-396.
143. Webster CS, Merry AF, Emmens DJ, Van Cotthem IC, Holland RL. A prospective clinical audit of central venous catheter use and complications in 1000 consecutive patients. *Anaesth Intensive Care*. 2003;31:80-86.
144. Brun-Buisson C, Doyon F, Sollet JP, Cochard JF, Cohen Y, Nitenberg G. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. *Intensive Care Med*. 2004 May;30:837-843. Epub 2004 Apr 2.
145. Carrasco MN, Bueno A, de las Cuevas C, et al. Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. *Intensive Care Med*. 2004 Apr;30:633-638. Epub 2004 Jan 13.
146. Hosoglu S, Akalin S, Kidir V, Suner A, Kayabas H, Geyik MF. Prospective surveillance study for risk factors of central venous catheter-related bloodstream infections. *Am J Infect Control*. 2004;32:131-134.
147. Leon C, Ruiz-Santana S, Rello J, et al, Cabana Study Group. Benefits of minocycline and rifampin-impregnated central venous catheters: a prospective, randomized, double-blind, controlled, multicenter trial. *Intensive Care Med*. 2004 Oct;30:1891-1899. Epub 2004 Jul 20.
148. Yucel N, Lefering R, Maegele M, et al. Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial. *J Antimicrob Chemother*. 2004 Dec;54:1109-1115. Epub 2004 Nov 10.
149. Darouiche RO, Raad II, Heard SO, et al, Catheter Study Group. A comparison of two antimicrobial-impregnated central venous catheters. *N Engl J Med*. 1999;340:1-8.
150. Norwood S, Wilkins HE III, Vallina VL, Fernandez LG, McLarty JW. The safety of prolonging the use of central venous catheters: a prospective analysis of the effects of using antiseptic-bonded catheters with daily site care. *Crit Care Med*. 2000;28:1376-1382.
151. Uldall PR, Merchant N, Woods F, Yarworski U, Vas S. Changing subclavian haemodialysis cannulas to reduce infection. *Lancet*. 1981;1:1373.
152. Sherertz RJ, Falk RJ, Huffman KA, Thomann CA, Mattern WD. Infections associated with subclavian Uldall catheters. *Arch Intern Med*. 1983;143:52-56.
153. Kozeny GA, Venezia FR, Bansal VK, Vertuno LL, Hano JE. Incidence of subclavian dialysis catheter-related infections. *Arch Intern Med*. 1984;144:1787-1789.
154. Dahlberg PJ, Yutuc WR, Newcomer KL. Subclavian hemodialysis catheter infections. *Am J Kidney Dis*. 1986;7:421-427.
155. Vanholder V, Hoenich N, Ringoir S. Morbidity and mortality of central venous catheter hemodialysis: a review of 10 years' experience. *Nephron*. 1987;47:274-279.
156. Almirall J, Gonzalez J, Rello J, et al. Infection of hemodialysis catheters: incidence and mechanisms. *Am J Nephrol*. 1989;9:454-459.
157. Rello J, Gatell JM, Almirall J, Campistol JM, Gonzalez J, Puig de la Bellacasa J. Evaluation of culture techniques for identification of catheter-related infection in hemodialysis patients. *Eur J Clin Microbiol Infect Dis*. 1989;8:620-622.
158. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. *Kidney Int*. 1991;40:934-938.
159. Dahlberg PJ, Agger WA, Singer JR, et al. Subclavian hemodialysis catheter infections: a prospective, randomized trial of an attachable silver-impregnated cuff for prevention of catheter-related infections. *Infect Control Hosp Epidemiol*. 1995;16:506-511.
160. Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. *Nephrol Dial Transplant*. 1999;14:1710-1714.
161. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. *Kidney Int*. 2000;58:2543-2545.
162. Contreras G, Liu PY, Elzinga L, et al. A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients. *Am J Kidney Dis*. 2003;42:315-324.
163. Nakada TA, Hirasawa H, Oda S, et al. Catheter-related infections in continuous hemodiafiltration in intensive care patients. *Blood Purif*. 2004;22:416-422. Epub 2004 Aug 13.
164. Naumovic RT, Jovanovic DB, Djukanovic LJ. Temporary vascular catheters for hemodialysis: a 3-year prospective study. *Int J Artif Organs*. 2004;27:848-854.
165. Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. *Nephrol Dial Transplant*. 2004;19:670-677.
166. Cheesbrough JS, Finch RG, Burden RP. A prospective study of the mechanisms of infection associated with hemodialysis catheters. *J Infect Dis*. 1986;154:579-589.
167. Capdevila JA, Segarra A, Planes AM, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. *Nephrol Dial Transplant*. 1993;8:231-234.
168. De Meester J, Vanholder R, De Roose J, Ringoir S. Factors and complications affecting catheter and technique survival with permanent single-lumen dialysis catheters. *Nephrol Dial Transplant*. 1994;9:678-683.
169. Lund GB, Trerotola SO, Scheel PF Jr, et al. Outcome of tunneled hemodialysis catheters placed by radiologists. *Radiology*. 1996;198:467-472.

170. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. *Ann Intern Med.* 1997;127:275-280.
171. Schnabel KJ, Simons ME, Zevallos GF, et al. Image-guided insertion of the Uldall tunneled hemodialysis catheter: technical success and clinical follow-up. *J Vasc Interv Radiol.* 1997;8:579-586.
172. Trerotola SO, Johnson MS, Shah H, et al. Tunneled hemodialysis catheters: use of a silver-coated catheter for prevention of infection: a randomized study. *Radiology.* 1998;207:491-496.
173. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. *J Am Soc Nephrol.* 1999;10:1045-1049.
174. Mokrzycki MH, Schroppel B, von Gersdorff G, Rush H, Zdunek MP, Feingold R. Tunneled-cuffed catheter associated infections in hemodialysis patients who are seropositive for the human immunodeficiency virus. *J Am Soc Nephrol.* 2000;11:2122-2127.
175. Jean G, Charra B, Chazot C, Vanel T, Terrat JC, Hurot JM. Long-term outcome of permanent hemodialysis catheters: a controlled study. *Blood Purif.* 2001;19:401-407.
176. Little MA, O'Riordan A, Lucey B, et al. A prospective study of complications associated with cuffed, tunneled haemodialysis catheters. *Nephrol Dial Transplant.* 2001;16:2194-2200.
177. Rocklin MA, Dwight CA, Callen LJ, Bispham BZ, Spiegel DM. Comparison of cuffed tunneled hemodialysis catheter survival. *Am J Kidney Dis.* 2001;37:557-563.
178. Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. *J Am Soc Nephrol.* 2002;13:2133-2139.
179. Jean G, Charra B, Chazot C, et al. Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. *Nephron.* 2002;91:399-405.
180. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with polysporin ointment. *J Am Soc Nephrol.* 2003;14:169-179.
181. Thomas JH, MacArthur RI, Pierce GE, Hermreck AS. Hickman-Broviac catheters: indications and results. *Am J Surg.* 1980;140:791-796.
182. Abraham JL, Mullen JL. A prospective study of prolonged central venous access in leukemia. *JAMA.* 1982;248:2868-2873.
183. Begala JE, Maher K, Cherry JD. Risk of infection associated with the use of Broviac and Hickman catheters. *Am J Infect Control.* 1982;10:17-23.
184. Quigley T, Sutherland DE, Howard RJ. Use of Hickman and Broviac central venous catheters in high risk patients. *Minn Med.* 1982;65:77-80.
185. Moore DJ, Keating J, McCann SC, Shanik DG. Venous access using a Hickman catheter. *Ir Med J.* 1983;76:35-36.
186. Reed WP, Newman KA. An improved technique for the insertion of Hickman catheters in patients with thrombocytopenia and granulocytopenia. *Surg Gynecol Obstet.* 1983;156:355-358.
187. Fuchs PC, Gustafson ME, King JT, Goodall PT. Assessment of catheter-associated infection risk with the Hickman right atrial catheter. *Infect Control.* 1984;5:226-230.
188. Landoy Z, Rotstein C, Lucey J, Fitzpatrick J. Hickman-Broviac catheter use in cancer patients. *J Surg Oncol.* 1984;26:215-218.
189. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. *Medicine (Baltimore).* 1984;63:189-200.
190. Smith RC, Hartemink RJ, Duggan D. Prolonged multipurpose venous access in burned patients: three years' experience with Hickman right atrial catheters. *J Trauma.* 1985;25:634-638.
191. Howard L, Claunch C, McDowell R, Timchalk M. Five years of experience in patients receiving home nutrition support with the implanted reservoir: a comparison with the external catheter. *JPEN J Parenter Enteral Nutr.* 1989;13:478-483.
192. Raviglione MC, Battan R, Pablos-Mendez A, Aceves-Casillas P, Mullen MP, Taranta A. Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome. *Am J Med.* 1989;86:780-786.
193. Early TF, Gregory RT, Wheeler JR, Snyder SO Jr, Gayle RG. Increased infection rate in double-lumen versus single-lumen Hickman catheters in cancer patients. *South Med J.* 1990;83:34-36.
194. Shivnan JC, McGuire D, Freedman S, et al. A comparison of transparent adherent and dry sterile gauze dressings for long-term central catheters in patients undergoing bone marrow transplant. *Oncol Nurs Forum.* 1991;18:1349-1356.
195. Mukau L, Talamini MA, Sitzmann JV, Burns RC, McGuire ME. Long-term central venous access vs other home therapies: complications in patients with acquired immunodeficiency syndrome. *JPEN J Parenter Enteral Nutr.* 1992;16:455-459.
196. Mullan FJ, Hood JM, Barros D'Sa AA. Use of the Hickman catheter for central venous access in patients with haematological disorders. *Br J Clin Pract.* 1992;46:167-170.
197. Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. *Ann Intern Med.* 1993;119:1168-1174.
198. Groeger JS, Lucas AB, Coit D, et al. A prospective, randomized evaluation of the effect of silver impregnated subcutaneous cuffs for preventing tunneled chronic venous access catheter infections in cancer patients. *Ann Surg.* 1993;218:206-210.
199. Keung YK, Watkins K, Chen SC, Groshen S, Silberman H, Douer D. Comparative study of infectious complications of different types of chronic central venous access devices. *Cancer.* 1994;73:2832-2837.
200. Williams N, Carlson GL, Scott NA, Irving MH. Incidence and management of catheter-related sepsis in patients receiving home parenteral nutrition. *Br J Surg.* 1994;81:392-394.
201. Howell PB, Walters PE, Donowitz GR, Farr BM. Risk factors for infection of adult patients with cancer who have tunneled central venous catheters. *Cancer.* 1995;75:1367-1375.
202. Rotstein C, Brock L, Roberts RS. The incidence of first Hickman catheter-related infection and predictors of catheter removal in cancer patients. *Infect Control Hosp Epidemiol.* 1995;16:451-458.
203. Brandt B, DePalma J, Irwin M, Shogan J, Lucke JF. Comparison of central venous catheter dressings in bone marrow transplant recipients. *Oncol Nurs Forum.* 1996;23:829-836.
204. Elishoov H, Or R, Strauss N, Engelhard D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients: a 5-year prospective study. *Medicine (Baltimore).* 1998;77:83-101.
205. Astagneau P, Maugat S, Tran-Minh T, et al. Long-term central venous catheter infection in HIV-infected and cancer patients: a multicenter cohort study. *Infect Control Hosp Epidemiol.* 1999;20:494-498.
206. Nouwen JL, Wielenga JJ, van Overhagen H, et al. Hickman catheter-related infections in neutropenic patients: insertion in the operating theater versus insertion in the radiology suite [published correction appears in *J Clin Oncol.* 2006;24:531]. *J Clin Oncol.* 1999;17:1304.
207. Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE. Longterm central venous access in gynecologic cancer patients. *J Am Coll Surg.* 2000;191:403-409.
208. Bothe A Jr, Piccione W, Ambrosino JJ, Benotti PN, Lokich JJ. Implantable central venous access system. *Am J Surg.* 1984;147:565-569.
209. van der Pijl H, Frissen PH. Experience with a totally implantable venous access device (Port-A-Cath) in patients with AIDS. *AIDS.* 1992;6:709-713.
210. Dega H, Eliasiewicz M, Gisselbrecht M, et al. Infections associated with totally implantable venous access devices (TIVAD) in human immunodeficiency virus-infected patients. *J Acquir Immune Defic Syndr Hum Retroviro.* 1996;13:146-154.
211. Biffi R, Corrado F, de Braud F, et al. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. *Eur J Cancer.* 1997;33:1190-1194.
212. Kuizon D, Gordon SM, Dolmatch BL. Single-lumen subcutaneous ports inserted by interventional radiologists in patients undergoing chemotherapy: incidence of infection and outcome of attempted catheter salvage. *Arch Intern Med.* 2001;161:406-410.
213. Biffi R, De Braud F, Orsi F, et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. *Cancer.* 2001;92:1204-1212.
214. Chang L, Tsai JS, Huang SJ, Shih CC. Evaluation of infectious complications of the implantable venous access system in a general oncologic population. *Am J Infect Control.* 2003;31:34-39.
215. Biffi R, Pozzi S, Agazzi A, et al. Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. *Ann Oncol.* 2004;15:296-300.
216. Whigham CJ, Goodman CJ, Fisher RG, Greenbaum MC, Thornby JI, Thomas JW. Infectious complications of 393 peripherally implantable venous

- access devices in HIV-positive and HIV-negative patients. *J Vasc Interv Radiol*. 1999;10:71-77.
217. Bodner LJ, Noshier JL, Patel KM, et al. Peripheral venous access ports: outcomes analysis in 109 patients. *Cardiovasc Intervent Radiol*. 2000;23:187-193.
218. Argenziano M, Catanese KA, Moazami N, et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. *J Heart Lung Transplant*. 1997;16:822-831.
219. Fischer SA, Trenholme GM, Costanzo MR, Piccione W. Infectious complications in left ventricular assist device recipients. *Clin Infect Dis*. 1997;24:18-23.
220. Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: treatment and outcome. *Clin Infect Dis*. 2005 Apr 15;40:1108-1115. Epub 2005 Mar 11.
221. Goldberg MJ, Rubenfire M, Kantrowitz A, et al. Intraaortic balloon pump insertion: a randomized study comparing percutaneous and surgical techniques. *J Am Coll Cardiol*. 1987;9:515-523.
222. Kluger DM, Maki DG. The risk of intravascular device-related (IVDR) bloodstream infection (BSI) in children and neonates: a meta-analysis of 88 published prospective studies [abstract]. In: *Abstracts of the IDSA 40th Meeting*. Chicago, Ill: University of Chicago; 2002:154. Abstract 623.
223. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. *Am J Infect Control*. 2002;30:458-475.
224. Centers for Disease Control and Prevention (CDC). Monitoring hospital-acquired infections to promote patient safety: United States, 1990-1999 [published correction appears in *MMWR Morb Mortal Wkly Rep*. 2000;49:189-190]. *MMWR Morb Mortal Wkly Rep*. 2000;49:149-153.
225. Joint Commission on the Accreditation of Healthcare Organizations. *Accreditation Manual for Hospitals*. Chicago, Ill: Joint Commission on the Accreditation of Healthcare Organizations; 1994:121-140.
226. Saint S. Prevention of intravascular catheter-associated infections. In: Shojania KG, Duncan BW, McDonald KM, Wachter RM, eds. *Making Health Care Safer: A Critical Analysis of Patient Safety Practices*. Rockville, Md: Agency for Healthcare Research and Quality; 2001:163-184.
227. Kurkchubasche AG, Smith SD, Rowe MI. Catheter sepsis in short-bowel syndrome. *Arch Surg*. 1992;127:21-24.
228. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. *Clin Infect Dis*. 2003 May 1;36:1103-1110. Epub 2003 Apr 14.
229. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection, I: pathogenesis and short-term devices. *Clin Infect Dis*. 2002 May 1;34:1232-1242. Epub 2002 Apr 2.
230. Maki DG. Marked differences in skin colonization of the insertion site for central venous, arterial and peripheral IV catheters: the major reason for differing risks of catheter related infection? [abstract]. *Program Abstr Intersci Conf Antimicrob Agents Chemother*. 1990;30:205.
231. Star RA. Treatment of acute renal failure. *Kidney Int*. 1998;54:1817-1831.
232. Randolph AG, Cook DJ, Gonzales CA, Brun-Buisson C. Tunneling short-term central venous catheters to prevent catheter-related infection: a meta-analysis of randomized, controlled trials. *Crit Care Med*. 1998;26:1452-1457.
233. Maki DG, Narans LL, Knasinski V, Kluger DM. Prospective, randomized, investigator-masked trial of a novel chlorhexidine-impregnated disk (Biopatch) on central venous and arterial catheters [abstract]. *Infect Cont Hosp Epidemiol*. 2000;21:96.
234. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. *Lancet*. 2000;355:1864-1868.
235. Rosenthal VD, Guzman S, Pezzotto SM, Crnich CJ. Effect of an infection control program using education and performance feedback on rates of intravascular device-associated bloodstream infections in intensive care units in Argentina. *Am J Infect Control*. 2003;31:405-409.
236. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. *Crit Care Med*. 2004; 32:2014-2020.
237. Warren DK, Zack JE, Mayfield JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. *Chest*. 2004;126:1612-1618.
238. Centers for Disease Control and Prevention (CDC). Reduction in central line-associated bloodstream infections among patients in intensive care units: Pennsylvania, April 2001-March 2005. *MMWR Morb Mortal Wkly Rep*. 2005;54:1013-1016.
239. Jarvis WR. Infection control and changing health-care delivery systems. *Emerg Infect Dis*. 2001;7:170-173.